

July 27, 2023

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 539524

Sub: Outcome of Board Meeting held on July 27, 2023

Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. July 27, 2023 inter-alia approved the following(s):

1. Convening of 29th Annual General Meeting (AGM) of the Company on Tuesday, September 12, 2023 through Video Conferencing/ Other Audio Visual Means (VC/OVAM).

Further, in continuation to our letter dated May 11, 2023, wherein we have intimated that the Board of Directors had recommended the final dividend for the FY 2022-23, subject to the approval by the shareholders in the 29th AGM. The record date for the purpose of payment of final dividend shall be August 11, 2023.

2. Declaration of interim dividend of **INR 6/-** per equity share (@ 60% on a face value of INR 10/- per share) for the FY 2023-24. The record date for the purpose of payment of interim dividend shall be August 11, 2023.
3. Appointment of Mr. Gurinder Singh Kalra (DIN: 10197218) and Mr. Rajit Mehta (DIN: 01604819) as Additional Directors in the category of Independent Directors of the Company for a term of three (3) years commencing from July 27, 2023 subject to approval of Shareholders of the Company in the 29th AGM.

Please also take note that Mr. Gurinder Singh Kalra and Mr. Rajit Mehta are not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority.

4. Appointment of M/s Chandrasekaran Associates, Company Secretaries as the Secretarial Auditors of the Company for the FY 2023-24.

The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars, if any, for point no. 3 & 4 above are enclosed herewith as “**Annexure A**”.

5. Grant of ESOPs to eligible employees, the salient features and other details of the same are enclosed herewith as “**Annexure B**”.

The Board Meeting commenced at 12:30 P.M. and concluded at 02:20 P.M.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

Sl. No.	Particulars	Details		
		Mr. Gurinder Singh Kalra (Independent Director)	Mr. Rajit Mehta (Independent Director)	M/s Chandrasekaran Associates (Secretarial Auditor)
1	Reasons for change viz appointment, resignation, removal, death or otherwise	Appointment		Appointment
2	Date of Appointment & term of appointment	<p><u>Date of Appointment:</u> July 27, 2023</p> <p><u>Term of Appointment:</u> The appointment of Mr. Gurinder Singh Kalra and Mr. Rajit Mehta as an Additional Directors in the category of Independent Directors shall be effective from July 27, 2023 for a term of three (3) years, subject to the approval of shareholders of the Company.</p>		Appointed on July 27, 2023 for FY 2023-24
3	Brief Profile (in case of appointment)	<p>Mr. Gurinder Singh Kalra has over 18 years of experience in technology equity research, predominantly at major investment banks. He also played a significant role in investment banking transactions, both capital raising and M&A for technology companies.</p> <p>Mr. Kalra is Chief Financial Officer in a biotech company which is listed on NASDAQ in the US. As CFO, he guided the company</p>	<p>Mr. Rajit Mehta is the Managing Director and Chief Executive Officer of Antara Senior Living Ltd., a subsidiary of Max India Limited that pioneers the concept of 'Age in Place' by developing senior living communities. He is also the Managing Director of Max India Ltd and provides oversight/ advisory for the HR function across the Max Group.</p> <p>Mr. Mehta is the Chairman of the CII task</p>	M/s Chandrasekaran Associates, Company Secretaries ("CACS"), is a firm of Company Secretaries having professional experience spanning over more than 30 years specializing in Secretarial Audit, Due Diligence, Assurance Audit, Corporate Compliance Management, Representation services and Transaction Advisory Services to the Corporate world on

		<p>through a SPAC merger and subsequent de-SPAC process. Mr. Kalra is having deep knowledge and understanding of capital markets and public/private fund raising process and has Investor Relations expertise.</p> <p>Mr. Kalra has completed his MBA from Harvard University and Bachelor of Science & Bachelor of Arts from Brown University.</p>	<p>force for Seniors, Co-chair NatHealth senior care vertical and a board member of ASLI (Association of Senior Living organizations in India). He has been recently appointed as the founding board member of Dementia India Alliance (DIA), a non-profit organization. He is also a Director on the Boards of Sheares Healthcare India Holdings (a Temasek company) and Medica Synergie Pvt. Ltd. (a hospital chain in East India).</p> <p>Mr. Mehta is a graduate in commerce, post graduate in Human Resources and has also attended an Advanced Management Program at INSEAD-France.</p>	various matters.
4	Disclosure of relationships between directors (in case of appointment of a director)	None	None	None

Salient features of ESOPs Granted:

Sl. No.	Particulars	Details of ESOP Plan, 2022	Details of RSU Plan, 2016
a)	Brief details of Options granted	2,37,500/- (Two Lakh Thirty Seven Thousand Five Hundred) Options have been granted on July 27, 2023	20,200/- (Twenty Thousand Two Hundred) Options have been granted on July 27, 2023
b)	Whether the scheme is in terms of SEBI (Share Based Employee Benefit and Sweat Equity) Regulations, 2021	Yes	Yes
c)	Total number of shares covered by these Options	2,37,500/- (Two Lakh Thirty Seven Thousand Five Hundred) equity shares of face value of Rs. 10/- each fully paid-up	20,200/- (Twenty Thousand Two Hundred) equity shares of face value of Rs. 10/- each fully paid-up
d)	Pricing formula	Exercise price per Option shall be determined by the Committee on each occasion of grant and the Committee shall have the discretion to allow up to 10% discount to the market price as on date of grant of option	Exercise price of Rs. 10/- per option
e)	Options vested	Not applicable	Not applicable
f)	Time within which Option may be exercised	5 years from the date of vesting or such other shorter period as may be decided by the Board of Directors including its Committee from time to time	5 years from the date of vesting
g)	Options exercised	Not applicable	Not applicable
h)	Money realized by exercise of Options	Not applicable	Not applicable
i)	The total number of shares arising as a result of exercise of Option	Not applicable	Not applicable

j)	Options lapsed	Not applicable	Not applicable
k)	Variation of terms of Options	There is no variation	There is no variation
l)	Brief details of significant terms	Options granted would vest not before one year and not later than four years from the date of grant of such options	Only vested Options can be exercised within the exercise period. Options shall vest after 1 year but within 4 years from the date of grant subject satisfaction of vesting conditions. Options not exercised within exercise period shall lapse.
m)	Subsequent changes or cancellation or exercise of such Options	There is no change, cancellation or exercise.	There is no change, cancellation or exercise.
n)	Diluted earnings per share pursuant to issue of equity shares on exercise of Options	Options are yet to be exercised	Options are yet to be exercised